Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Missing a crucial clinical update in a 200-page filing can cost far more than time. Vertex Pharmaceuticals’ biotech disclosures run deep—pipeline R&D spend, Trikafta royalty streams, gene-editing milestones, and collaboration payments are scattered across multiple forms. If you have ever searched “Vertex Pharmaceuticals SEC filings explained simply” or wondered how to track “Vertex Pharmaceuticals insider trading Form 4 transactions” before an FDA decision, you know the challenge.
Stock Titan solves it. Our AI-powered summaries break down every Vertex Pharmaceuticals annual report 10-K simplified, flagging revenue by therapy, risk factors tied to cystic-fibrosis competition, and progress on sickle-cell gene edits. Need the latest “Vertex Pharmaceuticals quarterly earnings report 10-Q filing” or an “8-K material events explained” alert after a pivotal trial read-out? We deliver real-time posts as soon as they hit EDGAR. You’ll also receive instant dashboards of “Vertex Pharmaceuticals Form 4 insider transactions real-time,” highlighting executive buys and sells so you can monitor “Vertex Pharmaceuticals executive stock transactions Form 4” without sifting through raw PDFs.
Use cases professionals rely on include:
- Rapid “Vertex Pharmaceuticals earnings report filing analysis” to compare CF revenue quarter-over-quarter.
- Monitoring board decisions in the “Vertex Pharmaceuticals proxy statement executive compensation” for incentive alignment.
- Staying ahead of partnership announcements with “understanding Vertex Pharmaceuticals SEC documents with AI.”
Whether you’re screening catalyst-driven trades or validating long-term models, our platform pairs comprehensive coverage with approachable insight—so every disclosure, from 10-K to Form 4, works for you.
Vertex Pharmaceuticals' EVP, CO & FO reported pre-planned stock sales under a Rule 10b5-1 trading plan. On 12/03/2025, the officer sold 7,000 shares of Vertex common stock at $451 per share and another 7,000 shares at $461 per share, both reported as open-market sales. These transactions were made pursuant to a company-approved Rule 10b5-1 trading plan that Mr. Wagner entered into on 5/9/2025. After the reported sales, he beneficially owned 37,725 shares of Vertex common stock directly.
Vertex Pharmaceuticals executive Dr. Ourania Tatsis reported an open market sale of company stock. On 12/03/2025, she sold 4,500 shares of Vertex common stock at a weighted average price of $449.99 per share, with individual sale prices ranging from $449.99 to $450.00. The transaction was coded as an open market sale and was made under a company-approved Rule 10b5-1 trading plan that Dr. Tatsis entered into on 08/21/2025. After this sale, she beneficially owned 46,793 shares of Vertex common stock directly.
A director of Vertex Pharmaceuticals (VRTX) reported a change in ownership of the company’s common stock. On 11/19/2025, the director recorded a transaction in which 800 shares of Vertex common stock were disposed of, coded as transaction type “G”. The shares were reported at a price of $0, indicating no cash consideration was recorded for this movement of shares in the form.
After this transaction, the director beneficially owns 6,315 shares of Vertex common stock in direct ownership. The filing is made on Form 4, which is used to report changes in insider ownership for directors, officers, and significant shareholders.
Vertex Pharmaceuticals (VRTX) executive Mark Atkinson reported a planned stock sale. As Executive Vice President and Chief Technical Operations Officer, he filed a Form 4 showing the sale of 2,500 shares of Vertex common stock on 11/17/2025 at a price of $434.58 per share.
After this transaction, he beneficially owned 16,852 shares directly. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on 08/11/2025, meaning the trades were pre-arranged under SEC rules designed to allow insiders to sell shares according to a preset plan.
Vertex Pharmaceuticals (VRTX) reported insider transactions by its Executive Chairman and Director, Dr. Jeffrey Leiden. On 11/13/2025 and 11/14/2025, he exercised stock options to acquire Vertex common stock at exercise prices of $91.05 and $86.52 per share, then sold portions of the shares in the open market.
Reported sales included 18,528 shares at a weighted average price of $440.22, 1,160 shares at $441.05, 32,234 shares at $440.30, and 21,330 shares at $441.35, plus smaller additional amounts. After these transactions, Dr. Leiden beneficially owned 24,026 Vertex shares directly and 440 shares through a 401(k), along with vested stock options. The filing notes the trades were made under a company-approved Rule 10b5-1 trading plan entered into on 8/6/2025.
Vertex Pharmaceuticals (VRTX) reported higher Q3 results. Total revenues were $3,076.4 million, up from $2,771.9 million a year ago, driven by TRIKAFTA/KAFTRIO at $2,653.6 million and ALYFTREK at $247.0 million. Net income rose to $1,082.9 million with diluted EPS of $4.20 versus $4.01. Operating income was $1,186.2 million.
Year-to-date, total revenues reached $8,811.3 million and net income was $2,762.1 million. U.S. product revenues were $1,976.3 million; Europe contributed $836.9 million. “Other revenues” of $30.7 million year-to-date included upfront payments related to povetacicept regional agreements. The balance sheet remained strong with cash and cash equivalents of $4,939.6 million and long-term marketable securities of $5,722.8 million. The company repurchased 4.5 million shares for $1.9 billion year-to-date and has $3.5 billion remaining under its 2025 authorization. CASGEVY and JOURNAVX contributed $16.9 million and $19.6 million, respectively, within other product revenues in Q3.
Vertex Pharmaceuticals (VRTX) reported an insider transaction by a director on a Form 4. On 10/15/2025, the director acquired 86.825 deferred stock units (Transaction Code A) at $410.31 per unit.
Each deferred stock unit represents one share of common stock and will be settled in stock upon the earliest of termination of board service, a change of control, disability, or death. Following the transaction, 2,638.332 derivative securities were beneficially owned directly.
Vertex Pharmaceuticals (VRTX) reported an insider equity award. Director Mr. Sachs acquired 115.766 deferred stock units on 10/15/2025 at $410.31 per unit. Following the transaction, he beneficially owns 15,457.433 derivative securities directly.
Each deferred stock unit represents one share of common stock and is settled in stock upon the earliest of termination of board service, a change of control, or the director’s disability or death.
Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), reported insider dispositions under a company-approved Rule 10b5-1 trading plan entered on 02/24/2025. On 10/01/2025 he disposed of 1,259 shares at $400, reducing his beneficial ownership to 16,347 shares, and on 10/02/2025 he sold 694 shares at $404.21, leaving 15,653 shares beneficially owned after the second transaction. The filing is signed by an attorney-in-fact on 10/03/2025.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
